Caribou Biosciences, Inc.
https://cariboubio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Caribou Biosciences, Inc.
Caribou Hit By Familiar Allo CAR-T Durability Problems
Like some of its allo CAR-T rivals, CB-010’s early promise has fallen away, but Caribou still hopes a higher dose can bring with it real durability of response.
Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.
PD-1 Knockout Could Be Caribou’s Key To Allo CAR-T Success
While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.
5 Dealmaking Trends To Watch In 2022
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice